Latest News on Novartis
Showing of 0 - 10 from 59 results
Novartis - Total results - 59
Nov 18, 2014
Beyond tablets: World's biggest drugmaker Novartis taking a closer look at techThe Swiss group has already taken tentative steps, signing a deal with Google Inc in July to develop contact lenses to help diabetics track blood glucose levels
Nov 02, 2014
DIPP looks into Cipla's demand that Novartis's patent for respiratory drug be revokedThe Department of Industrial Policy and Promotion (DIPP) has started the exercise on Cipla's demand.
Oct 13, 2014
Ouch: NPPA slaps Novartis with Rs 300 cr fine for over pricingThe NPPA had put diclofenac, a key ingredient of Novartis's Voveran, under direct price control in May 2013.
Oct 08, 2014
Why did PM Modi agree to give away India’s patent sovereignty to Americans?The agreement with the US in the sector will affect India’s sovereignty and the lives of its present and future generations.
Sep 01, 2014
Novartis banks on new blockbuster heart failure drug to hit new highsInvestigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multibillion-dollar sales opportunity.
Jul 22, 2014
Lupin, US firms plan bids for range of GSK drugs to be auctionedAssuming a multiple of between two and three times those sales, the assets on the block could fetch between $3.5 billion and $5.0 billion.
Jul 16, 2014
Novartis, Google working on smart contact lensesArray
Dec 31, 2013
To the brink and back: Key business events in 2013The RBI starting the year off with rate cuts and then reversing its stance on concerns about widening current account deficit. Fears that the US Federal Reserve will start cutting its bond purchase programme sooner than expected only added to the worries. Foreign funds pulled out of the Indian equities and debt in hoards.
Dec 29, 2013
Pharma sector registers single digit growth in 2013; regulators increase scrutinyThe Indian pharma sector, estimated to be around Rs 1.5 lakh crore, recorded single digit growth for the first time in several years on account of deeper price cuts under pricing policy and selective boycott of companies by the retailers.
Jun 20, 2013
EU fines Ranbaxy, 8 others for blocking cheaper drugsThe punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said "pay-for-delay" deals lead to consumers paying as much as 20 percent more for their medicines.